151
|
Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol 2017; 16:917-924. [PMID: 28919059 PMCID: PMC5646369 DOI: 10.1016/s1474-4422(17)30284-3] [Citation(s) in RCA: 148] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 06/29/2017] [Accepted: 07/31/2017] [Indexed: 11/24/2022]
Abstract
Background Post-mortem studies have not identified an association between beta-amyloid or tau and rates of hippocampal atrophy in Alzheimer’s disease. TAR DNA binding protein of 43kDa (TDP-43) is another protein recently linked to Alzheimer’s disease. We aimed to determine whether hippocampal TDP-43 is associated with faster rates of hippocampal atrophy. Methods Two-hundred ninety-eight autopsied cases with Alzheimer’s spectrum disease that had antemortem head MRI scans between 1/1/1999–12/31/2012 recruited into the Mayo Clinic Alzheimer’s Disease Research Center or Patient Registry/Study of Aging were analyzed. TDP-43 immunohistochemistry was performed and cases classified as follows: no TDP-43; TDP-43 restricted to amygdala; and TDP-43 spreading into hippocampus. Eight-hundred sixteen MRI scans, spanning 1.0–11.2 years prior to death, were analyzed. We utilized longitudinal FreeSurfer and tensor-based morphometry with symmetric normalization to calculate hippocampal volume on all serial MRI and performed linear mixed-effects regression models to estimate associations between TDP-43 and rate of hippocampal atrophy, and determine the trajectory of TDP-43 associated atrophy. Findings One-hundred forty-one cases showed no TDP-43, 33 had TDP-43 restricted to the amygdala and 124 had TDP-43 in hippocampus. Cases with hippocampal TDP-43 had faster rates of hippocampal atrophy compared to cases with amygdala-only TDP-43 and those without TDP-43 in cases with an intermediate-high likelihood of having Alzheimer’s disease (N=261). Hippocampal TDP-43 was not associated with rate of hippocampal atrophy in cases with low likelihood of having Alzheimer’s disease (N=37). The trajectory analysis suggested that increased rates of TDP-43 associated hippocampal atrophy may be occurring at least 10-years before death. Results were similar for FreeSurfer and tensor-based morphometry. Interpretation In Alzheimer’s disease, TDP-43 should be considered a potential factor related to increased rates of hippocampal atrophy. Given the importance of hippocampal atrophy in Alzheimer’s disease, it is imperative that we develop techniques for detecting TDP-43 pathology in-vivo. Funding National Institute of Aging
Collapse
|
152
|
Skogseth R, Hortobágyi T, Soennesyn H, Chwiszczuk L, Ffytche D, Rongve A, Ballard C, Aarsland D. Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. J Alzheimers Dis 2017; 59:1139-1152. [DOI: 10.3233/jad-170274] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Ragnhild Skogseth
- Haraldsplass Deaconess Hospital, Kavli Research Centre for Geriatrics and Dementia, Bergen, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Tibor Hortobágyi
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- MTA-DE Cerebrovascular and Neurodegenerative Research Group, Departments of Neurology & Neuropathology, University of Debrecen, Debrecen, Hungary
| | - Hogne Soennesyn
- Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
| | - Luiza Chwiszczuk
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway
| | - Dominic Ffytche
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Arvid Rongve
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Research and Innovation, Helse Fonna, Haugesund Hospital, Haugesund, Norway
| | - Clive Ballard
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- University of Exeter Medical School, University of Exeter, Exeter, UK
| | - Dag Aarsland
- Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
| |
Collapse
|
153
|
Spires-Jones TL, Attems J, Thal DR. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 2017; 134:187-205. [PMID: 28401333 PMCID: PMC5508034 DOI: 10.1007/s00401-017-1709-7] [Citation(s) in RCA: 264] [Impact Index Per Article: 37.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 03/30/2017] [Accepted: 04/01/2017] [Indexed: 02/06/2023]
Abstract
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal lobar degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) have in common that protein aggregates represent pathological hallmark lesions. Amyloid β-protein, τ-protein, α-synuclein, and TDP-43 are the most frequently aggregated proteins in these disorders. Although they are assumed to form disease-characteristic aggregates, such as amyloid plaques and neurofibrillary tangles in AD or Lewy bodies in LBD/PD, they are not restricted to these clinical presentations. They also occur in non-diseased individuals and can co-exist in the same brain without or with a clinical picture of a distinct dementing or movement disorder. In this review, we discuss the co-existence of these pathologies and potential additive effects in the human brain as well as related functional findings on cross-seeding and molecular interactions between these aggregates/proteins. We conclude that there is evidence for interactions at the molecular level as well as for additive effects on brain damage by multiple pathologies occurring in different functionally important neurons. Based upon this information, we hypothesize a cascade of events that may explain general mechanisms in the development of neurodegenerative disorders: (1) distinct lesions are a prerequisite for the development of a distinct disease (e.g., primary age-related tauopathy for AD), (2) disease-specific pathogenic events further trigger the development of a specific disease (e.g., Aβ aggregation in AD that exaggerate further Aβ and AD-related τ pathology), (3) the symptomatic disease manifests, and (4) neurodegenerative co-pathologies may be either purely coincidental or (more likely) have influence on the disease development and/or its clinical presentation.
Collapse
Affiliation(s)
- Tara L Spires-Jones
- Centre for Dementia Prevention, and Euan MacDonald Centre for Motor Neurone Disease, The University of Edinburgh Centre for Cognitive and Neural Systems, 1 George Square, Edinburgh, EH8 9JZ, UK.
| | - Johannes Attems
- Institute of Neuroscience, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK
| | - Dietmar Rudolf Thal
- Departement Neurowetenschappen, Katholieke Universiteit Leuven, Herestraat 49, 3000, Leuven, Belgium
- Departement Pathologische Ontleedkunde, UZ Leuven, Herestraat 49, 3000, Leuven, Belgium
| |
Collapse
|
154
|
Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017; 134:171-186. [PMID: 28488154 PMCID: PMC5663642 DOI: 10.1007/s00401-017-1717-7] [Citation(s) in RCA: 400] [Impact Index Per Article: 57.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 04/28/2017] [Accepted: 04/29/2017] [Indexed: 12/14/2022]
Abstract
Longitudinal clinical-pathological studies have increasingly recognized the importance of mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular disease pathologies) as important factors in the development of Alzheimer's disease (AD) and other forms of dementia. Older persons with AD pathology, often have concomitant cerebrovascular disease pathologies (macroinfarcts, microinfarcts, atherosclerosis, arteriolosclerosis, cerebral amyloid angiopathy) as well as other concomitant neurodegenerative disease pathologies (Lewy bodies, TDP-43, hippocampal sclerosis). These additional pathologies lower the threshold for clinical diagnosis of AD. Many of these findings from pathologic studies, especially for CVD, have been confirmed using sophisticated neuroimaging technologies. In vivo biomarker studies are necessary to provide an understanding of specific pathologic contributions and time course relationships along the spectrum of accumulating pathologies. In this review, we provide a clinical-pathological perspective on the role of multiple brain pathologies in dementia followed by a review of the available clinical and biomarker data on some of the mixed pathologies.
Collapse
Affiliation(s)
- Alifiya Kapasi
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, USA
- Department of Pathology, Rush University Medical Center, Chicago, USA
| | - Charles DeCarli
- Department of Neurology, University of California, Davis, Sacramento, USA
| | - Julie A Schneider
- Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, USA.
- Department of Pathology, Rush University Medical Center, Chicago, USA.
- Department of Neurological Sciences, Rush University Medical Center, Chicago, USA.
| |
Collapse
|
155
|
Garnier C, Devred F, Byrne D, Puppo R, Roman AY, Malesinski S, Golovin AV, Lebrun R, Ninkina NN, Tsvetkov PO. Zinc binding to RNA recognition motif of TDP-43 induces the formation of amyloid-like aggregates. Sci Rep 2017; 7:6812. [PMID: 28754988 PMCID: PMC5533730 DOI: 10.1038/s41598-017-07215-7] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 06/23/2017] [Indexed: 12/12/2022] Open
Abstract
Aggregation of TDP-43 (transactive response DNA binding protein 43 kDa) is a hallmark of certain forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Moreover, intracellular TDP-43-positive inclusions are often found in other neurodegenerative diseases. Recently it was shown that zinc ions can provoke the aggregation of endogenous TDP-43 in cells, allowing to assume a direct interaction of TDP-43 with zinc ions. In this work, we investigated zinc binding to the 102-269 TDP-43 fragment, which comprise the two RNA recognition motifs. Using isothermal titration calorimetry, mass spectrometry, and differential scanning fluorimetry, we showed that zinc binds to this TDP-43 domain with a dissociation constant in the micromolar range and modifies its tertiary structure leading to a decrease of its thermostability. Moreover, the study by dynamic light scattering and negative stain electron microscopy demonstrated that zinc ions induce auto-association process of this TDP-43 fragment into rope-like structures. These structures are thioflavin-T-positive allowing to hypothesize the direct implication of zinc ions in pathological aggregation of TDP-43.
Collapse
Affiliation(s)
- Cyrille Garnier
- Mécanismes Moléculaires dans les Démences Neurodégénératives, Université de Montpellier, EPHE, INSERM, U1198, F-34095, Montpellier, France
- Université de Rennes 1, Campus de Beaulieu, 35042, Rennes cedex, France
| | - François Devred
- Aix-Marseille Univ, Inserm, CRO2 UMR_S 911, Faculté de Pharmacie, 13385, Marseille, France
| | - Deborah Byrne
- Institut de Microbiologie de la Méditerranée, CNRS, FR3479, Aix-Marseille Université, Marseille, France
| | - Rémy Puppo
- Institut de Microbiologie de la Méditerranée, CNRS, FR3479, Aix-Marseille Université, Marseille, France
| | - Andrei Yu Roman
- Aix-Marseille Univ, Inserm, CRO2 UMR_S 911, Faculté de Pharmacie, 13385, Marseille, France
- Institute of Physiologically Active Compounds, RAS, 142432, Chernogolovka, Russian Federation
| | - Soazig Malesinski
- Aix-Marseille Univ, Inserm, CRO2 UMR_S 911, Faculté de Pharmacie, 13385, Marseille, France
| | - Andrey V Golovin
- Lomonosov Moscow State University, Moscow, 119991, Russian Federation
| | - Régine Lebrun
- Institut de Microbiologie de la Méditerranée, CNRS, FR3479, Aix-Marseille Université, Marseille, France
| | - Natalia N Ninkina
- Institute of Physiologically Active Compounds, RAS, 142432, Chernogolovka, Russian Federation.
- School of Biosciences, Cardiff University, Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX, UK.
| | - Philipp O Tsvetkov
- Aix-Marseille Univ, Inserm, CRO2 UMR_S 911, Faculté de Pharmacie, 13385, Marseille, France.
| |
Collapse
|
156
|
Hosaka Y, Inoshita T, Shiba-Fukushima K, Cui C, Arano T, Imai Y, Hattori N. Reduced TDP-43 Expression Improves Neuronal Activities in a Drosophila Model of Perry Syndrome. EBioMedicine 2017. [PMID: 28625517 PMCID: PMC5514405 DOI: 10.1016/j.ebiom.2017.06.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Parkinsonian Perry syndrome, involving mutations in the dynein motor component dynactin or p150Glued, is characterized by TDP-43 pathology in affected brain regions, including the substantia nigra. However, the molecular relationship between p150Glued and TDP-43 is largely unknown. Here, we report that a reduction in TDP-43 protein levels alleviates the synaptic defects of neurons expressing the Perry mutant p150G50R in Drosophila. Dopaminergic expression of p150G50R, which decreases dopamine release, disrupts motor ability and reduces the lifespan of Drosophila. p150G50R expression also causes aggregation of dense core vesicles (DCVs), which contain monoamines and neuropeptides, and disrupts the axonal flow of DCVs, thus decreasing synaptic strength. The above phenotypes associated with Perry syndrome are improved by the removal of a copy of Drosophila TDP-43 TBPH, thus suggesting that the stagnation of axonal transport by dynactin mutations promotes TDP-43 aggregation and interferes with the dynamics of DCVs and synaptic activities. Fly model of Perry syndrome exhibits motor disturbance and impaired dopamine release. Perry mutation in dynactin produces aggregation of dense core vesicles (DCVs) in axons and disrupts axonal flux of DCVs. Removal of a copy of the TDP-43 gene improves retrograde flux of DCVs.
Parkinsonian Perry syndrome (PS), caused by mutations in a component of the retrograde transport complex, Dynactin, is pathologically characterized by the accumulation of an RNA-binding protein, TDP-43, in affected neurons. The neuronal accumulation of TDP-43 is observed in various neurodegenerative diseases including amyotrophic lateral sclerosis and Alzheimer's disease. We report that decreased TDP-43 expression improves defects in the axonal transport of dense core vesicles and in the dopamine release in a Drosophila PS model. This study provides insight into the possibility that a transient decrease in TDP-43 in neurons may be a promising therapeutic approach for treating neurodegenerative disorders associated with TDP-43 pathology, including PS.
Collapse
Affiliation(s)
- Yuka Hosaka
- Department of Neurology, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Tsuyoshi Inoshita
- Department of Treatment and Research in Multiple Sclerosis and Neuro-intractable Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Kahori Shiba-Fukushima
- Department of Treatment and Research in Multiple Sclerosis and Neuro-intractable Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Changxu Cui
- Department of Research for Parkinson's Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Taku Arano
- Center for Genomic and Regenerative Medicine, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan
| | - Yuzuru Imai
- Department of Neurology, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan; Department of Treatment and Research in Multiple Sclerosis and Neuro-intractable Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan.
| | - Nobutaka Hattori
- Department of Neurology, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan; Department of Treatment and Research in Multiple Sclerosis and Neuro-intractable Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan; Department of Research for Parkinson's Disease, Juntendo University, Graduate School of Medicine, Tokyo 113-8421, Japan.
| |
Collapse
|
157
|
Novel approach for accurate tissue-based protein colocalization and proximity microscopy. Sci Rep 2017; 7:2668. [PMID: 28572629 PMCID: PMC5454019 DOI: 10.1038/s41598-017-02735-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Accepted: 04/19/2017] [Indexed: 11/16/2022] Open
Abstract
Fluorescence colocalization microscopy is frequently used to assess potential links between distinct molecules; however, this method can lead to striking false-positive results and erroneous conclusions. Here we developed a novel approach with more sophisticated mathematical colocalization analyses together with visualization of physical proximity using fluorescence resonance energy transfer (FRET). To verify our results we used the proximity ligation assay (PLA). With these methods we could demonstrate that distinct neurodegeneration-related proteins either not or only rarely interact in human brain tissue.
Collapse
|
158
|
Abstract
PURPOSE OF THE REVIEW A wide array of sleep and circadian deficits have been observed in patients with Alzheimer's Disease (AD). However, the vast majority of these studies have focused on later-stage AD, and do not shed light on the possibility that circadian dysfunction contributes to AD pathogenesis. The goal of this review it to examine the evidence supporting or refuting the hypothesis that circadian dysfunction plays an important role in early AD pathogenesis or AD risk in humans. RECENT FINDINGS Few studies have addressed the role of the circadian system in very early AD, or prior to AD diagnosis. AD appears to have a long presymtomatic phase during which pathology is present but cognition remains normal. Studies evaluating circadian function in cognitively-normal elderly or early-stage AD have thus far not incorporated AD biomarkers. Thus, the cause-and-effect relationship between circadian dysfunction and early-stage AD remains unclear. SUMMARY Circadian dysfunction becomes apparent in AD as dementia progresses, but it is unknown at which point in the pathogenic process rhythms begin to deteriorate. Further, it is unknown if exposure to circadian disruption in middle age increases AD risk later in life. This review address gaps in current knowledge on this topic, and proposes several critical directions for future research which might help to clarify the potential pathogenic role of circadian clock dysfunction in AD.
Collapse
Affiliation(s)
- Erik S. Musiek
- Dept. of Neurology, Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis MO, USA
| |
Collapse
|
159
|
Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS, Machulda MM, Weigand SD, Boeve BF, Kantarci K, Petrucelli L, Lowe VJ, Jack CR, Petersen RC, Parisi JE, Dickson DW. Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol 2017; 133:705-715. [PMID: 28160067 DOI: 10.1007/s00401-017-1681-2] [Citation(s) in RCA: 114] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 01/20/2017] [Accepted: 01/22/2017] [Indexed: 12/13/2022]
Abstract
We investigate whether there is any association between the Braak neurofibrillary tangle (NFT) stage and clinical and MRI features in definite primary age-related tauopathy (PART). We analysed 52 cases with a Braak NFT tangle stage >0 and ≤IV, and a Thal phase of 0 (no beta-amyloid present). Twenty-nine (56%) were female. Median age at death was 88 years (IQR 82-92 years). Fifteen (29%) were TDP-positive (75% TDP stage I), 16 (31%) had argyrophilic grain disease and three (6%) had alpha-synuclein-positive Lewy bodies. TDP-43 inclusion when present were rare and predominantly perivascular. Of the 15 with TDP-43, three showed a moderate number of inclusions and also had hippocampal sclerosis, neuronal intranuclear inclusions and fine neurites of the CA1 region of the hippocampus. Four cases (8%) had an apolipoprotein epsilon 4 (APOE4) allele. There was a significant correlation between age at death and Braak NFT stage (r = 0.32, p = 0.02). After accounting for age at clinical examination, there were significant associations between Braak NFT stage, and WAIS-R Block Design and Trail Making Tests A and B, with higher Braak stage associated with poorer performances. Thirty of the 52 cases had completed an antemortem volumetric head MRI. Two separate MRI analyses revealed an association between higher Braak NFT stage and grey matter atrophy in the head of the left hippocampus. There were no significant clinical or radiologic associations with TDP-43. Findings from this study demonstrate that aggregated tau distribution is associated with poorer cognitive performance, as well as atrophy, in the absence of beta-amyloid. These findings support the parcellation of definite PART as a useful construct. The relatively low frequencies of APOE4, TDP-43, Lewy bodies, and hippocampal sclerosis, and the rarity and morphology of TDP-43 lesions are noted contrasts to what is typically observed in Alzheimer's disease of the old.
Collapse
Affiliation(s)
- Keith A Josephs
- Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA.
- Movement Disorders, Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN, USA.
| | | | - Nirubol Tosakulwong
- Biostatistics, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Jennifer L Whitwell
- Radiology Research, Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - David S Knopman
- Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | - Mary M Machulda
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | - Stephen D Weigand
- Biostatistics, Department of Health Science Research, Mayo Clinic, Rochester, MN, USA
| | - Bradley F Boeve
- Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | - Kejal Kantarci
- Radiology Research, Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | | | - Val J Lowe
- Radiology Research, Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Clifford R Jack
- Radiology Research, Department of Radiology, Mayo Clinic, Rochester, MN, USA
| | - Ronald C Petersen
- Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA
| | - Joseph E Parisi
- Neuropathology, Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | | |
Collapse
|
160
|
Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW, Nelson PT. Overlapping but distinct TDP-43 and tau pathologic patterns in aged hippocampi. Brain Pathol 2017; 28:264-273. [PMID: 28281308 DOI: 10.1111/bpa.12505] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Accepted: 03/06/2017] [Indexed: 01/06/2023] Open
Abstract
Intracellular proteinaceous aggregates (inclusion bodies) are almost always detectable at autopsy in brains of elderly individuals. Inclusion bodies composed of TDP-43 and tau proteins often coexist in the same brain, and each of these pathologic biomarkers is associated independently with cognitive impairment. However, uncertainties remain about how the presence and neuroanatomical distribution of inclusion bodies correlate with underlying diseases including Alzheimer's disease (AD). To address this knowledge gap, we analyzed data from the University of Kentucky AD Center autopsy series (n = 247); none of the brains had frontotemporal lobar degeneration. A specific question for this study was whether neurofibrillary tangle (NFT) pathology outside of the Braak NFT staging scheme is characteristic of brains with TDP-43 pathology but lacking AD, that is those with cerebral age-related TDP-43 with sclerosis (CARTS). We also tested whether TDP-43 pathology is associated with comorbid AD pathology, and whether argyrophilic grains are relatively likely to be present in cases with, vs. without, TDP-43 pathology. Consistent with prior studies, hippocampal TDP-43 pathology was associated with advanced AD - Braak NFT stages V/VI. However, argyrophilic grain pathology was not more common in cases with TDP-43 pathology in this data set. In brains with CARTS (TDP-43[+]/AD[-] cases), there were more NFTs in dentate granule neurons than were seen in TDP-43[-]/AD[-] cases. These dentate granule cell NFTs could provide a proxy indicator of CARTS pathology in cases lacking substantial AD pathology. Immunofluorescent experiments in a subsample of cases found that, in both advanced AD and CARTS, approximately 1% of dentate granule neurons were PHF-1 immunopositive, whereas ∼25% of TDP-43 positive cells showed colocalized PHF-1 immunoreactivity. We conclude that NFTs in hippocampal dentate granule neurons are often present in CARTS, and TDP-43 pathology may be secondary to or occurring in parallel with tauopathy.
Collapse
Affiliation(s)
- Vanessa D Smith
- Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY
| | - Adam D Bachstetter
- Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY.,Department of Neuroscience, University of Kentucky, Lexington, KY
| | - Eseosa Ighodaro
- Department of Neuroscience, University of Kentucky, Lexington, KY.,Sanders Brown Center on Aging, University of Kentucky, Lexington, KY
| | - Kelly Roberts
- Spinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY
| | - Erin L Abner
- Sanders Brown Center on Aging, University of Kentucky, Lexington, KY.,Department of Epidemiology, University of Kentucky, Lexington, KY
| | - David W Fardo
- Department of Biostatistics, University of Kentucky, Lexington, KY
| | - Peter T Nelson
- Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY.,Department of Neuroscience, University of Kentucky, Lexington, KY.,Sanders Brown Center on Aging, University of Kentucky, Lexington, KY
| |
Collapse
|
161
|
Hudry E. New Therapeutic Avenue for ALS: Avoiding a Fatal Encounter of TDP-43 at the Mitochondria. Mol Ther 2017; 25:10-11. [PMID: 28129105 DOI: 10.1016/j.ymthe.2016.12.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Affiliation(s)
- Eloise Hudry
- Alzheimer's Disease Research Unit, Harvard Medical School and Massachusetts General Hospital, 114 16th St., Charlestown, MA 02129, USA.
| |
Collapse
|